Research programme: tetrahydrofolate dehydrogenase inhibitors - Cloud PharmaceuticalsAlternative Names: Anti-parasitic therapeutics - Cloud Pharmaceuticals; DHFR inhibitors - Cloud Pharmaceuticals; Dihydrofolate reductase inhibtors - Cloud Pharmaceuticals; pfDHFR inhibtor - Cloud Pharmaceuticals
Latest Information Update: 31 Jul 2014
At a glance
- Originator Cloud Pharmaceuticals
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Malaria
Most Recent Events
- 14 Jul 2014 Early research in Malaria in USA (unspecified route)